Isabel Campos-Varela1,2, Jennifer L Dodge3, Marina Berenguer4, René Adam5, Didier Samuel5,6, Fabrizio Di Benedetto7, Vincent Karam5, Luca S Belli8, Christophe Duvoux9, Norah A Terrault10. 1. Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Barcelona, Spain. 2. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Madrid, Spain. 3. Department of Surgery, University of California-San Francisco, San Francisco, CA. 4. Liver Unit, La Fe University Hospital, Ciberehd, IISLaFe, University of Medicine, Valencia, Spain. 5. Centre Hépato-Biliaire, AP-HP Hôpital Paul Brousse, University Paris Sud Villejuif, Paris, France. 6. University Paris Sud-Paris Saclay, Paris, France. 7. Hepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, University of Modena and Reggio Emilia, Modena, Italy. 8. Department of Hepatology and Gastroenterology, Niguarda Hospital, Milan, Italy. 9. Department of Hepatology, University Hospital of Henri Mondor-APHP, Paris Est University (UPEC), Créteil, France. 10. Keck School of Medicine, University of Southern California, Los Angeles, CA.
Abstract
BACKGROUND: We evaluated trends and outcomes of liver transplantation (LT) recipients with/without HIV infection. METHODS: LT recipients between 2008 and 2015 from the United Network for Organ Sharing and Organ Procurement and Transplantation Network and European Liver Transplant Registry were included. Trends and characteristics related to survival among LT recipients with HIV infection were determined. RESULTS: Among 73 206 LT patients, 658 (0.9%) were HIV-infected. The proportion of LT HIV-infected did not change over time (P-trend = 0.16). Hepatitis C virus (HCV) as indication for LT decreased significantly for HIV-infected and HIV-uninfected patients (P-trends = 0.008 and <0.001). Three-year cumulative graft survival in LT recipients with and without HIV infection was 64.4% and 77.3%, respectively (P < 0.001), with improvements over time for both, but with HIV-infected patients having greater improvements (P-trends = 0.02 and 0.03). Adjusted risk of graft loss was 41% higher in HIV-infected versus HIV-uninfected (adjusted hazard ratio [aHR], 1.41; P < 0.001). Among HIV-infected, model of end-stage liver disease (aHR, 1.04; P < 0.001), body mass index <21 kg/m (aHR, 1.61; P = 0.006), and HCV (aHR, 1.83; P < 0.001) were associated with graft loss, whereas more recent period of LT 2012-2015 (aHR, 0.58; P = 0.001) and donor with anoxic cause of death (aHR, 0.51; P = 0.007) were associated with lower risk of graft loss. CONCLUSIONS: Patients with HIV infection account for only 1% of LTs in United States and Europe, with fewer LT for HCV disease over time. A static rate of LT among HIV-infected patients may reflect improvements in cirrhosis management and/or persistent barriers to LT. Graft and patient survival among HIV-infected LT recipients have shown improvement over time.
BACKGROUND: We evaluated trends and outcomes of liver transplantation (LT) recipients with/without HIV infection. METHODS: LT recipients between 2008 and 2015 from the United Network for Organ Sharing and Organ Procurement and Transplantation Network and European Liver Transplant Registry were included. Trends and characteristics related to survival among LT recipients with HIV infection were determined. RESULTS: Among 73 206 LT patients, 658 (0.9%) were HIV-infected. The proportion of LT HIV-infected did not change over time (P-trend = 0.16). Hepatitis C virus (HCV) as indication for LT decreased significantly for HIV-infected and HIV-uninfected patients (P-trends = 0.008 and <0.001). Three-year cumulative graft survival in LT recipients with and without HIV infection was 64.4% and 77.3%, respectively (P < 0.001), with improvements over time for both, but with HIV-infected patients having greater improvements (P-trends = 0.02 and 0.03). Adjusted risk of graft loss was 41% higher in HIV-infected versus HIV-uninfected (adjusted hazard ratio [aHR], 1.41; P < 0.001). Among HIV-infected, model of end-stage liver disease (aHR, 1.04; P < 0.001), body mass index <21 kg/m (aHR, 1.61; P = 0.006), and HCV (aHR, 1.83; P < 0.001) were associated with graft loss, whereas more recent period of LT 2012-2015 (aHR, 0.58; P = 0.001) and donor with anoxic cause of death (aHR, 0.51; P = 0.007) were associated with lower risk of graft loss. CONCLUSIONS: Patients with HIV infection account for only 1% of LTs in United States and Europe, with fewer LT for HCV disease over time. A static rate of LT among HIV-infected patients may reflect improvements in cirrhosis management and/or persistent barriers to LT. Graft and patient survival among HIV-infected LT recipients have shown improvement over time.
Authors: Rainer Weber; Caroline A Sabin; Nina Friis-Møller; Peter Reiss; Wafaa M El-Sadr; Ole Kirk; Francois Dabis; Matthew G Law; Christian Pradier; Stephane De Wit; Börje Akerlund; Gonzalo Calvo; Antonella d'Arminio Monforte; Martin Rickenbach; Bruno Ledergerber; Andrew N Phillips; Jens D Lundgren Journal: Arch Intern Med Date: 2006 Aug 14-28
Authors: Norah A Terrault; Michelle E Roland; Thomas Schiano; Lorna Dove; Michael T Wong; Fred Poordad; Margaret V Ragni; Burc Barin; David Simon; Kim M Olthoff; Lynt Johnson; Valentina Stosor; Dushyantha Jayaweera; John Fung; Kenneth E Sherman; Aruna Subramanian; J Michael Millis; Douglas Slakey; Carl L Berg; Laurie Carlson; Linda Ferrell; Donald M Stablein; Jonah Odim; Lawrence Fox; Peter G Stock Journal: Liver Transpl Date: 2012-06 Impact factor: 5.799
Authors: Jean-Charles Duclos-Vallée; Cyrille Féray; Mylène Sebagh; Elina Teicher; Anne-Marie Roque-Afonso; Bruno Roche; Daniel Azoulay; René Adam; Henri Bismuth; Denis Castaing; Daniel Vittecoq; Didier Samuel Journal: Hepatology Date: 2008-02 Impact factor: 17.425
Authors: Laura Pimpin; Helena Cortez-Pinto; Francesco Negro; Emily Corbould; Jeffrey V Lazarus; Laura Webber; Nick Sheron Journal: J Hepatol Date: 2018-05-17 Impact factor: 25.083
Authors: Isabel Campos-Varela; Jennifer L Dodge; Norah A Terrault; Danielle Brandman; Jennifer C Price Journal: Am J Transplant Date: 2021-07-08 Impact factor: 9.369
Authors: Thomas G Cotter; Jennifer Wang; Sarah R Lieber; Matthew A Odenwald; Nicole E Rich; Jorge A Marrero; Amit G Singal; Mack C Mitchell; Andrew Aronsohn; Michael Charlton; John Fung Journal: Transplant Direct Date: 2021-06-08